The 6\textsuperscript{th} International Symposium in Quantitative Pharmacology \textbullet{} 2017

December 1\textsuperscript{st}-2\textsuperscript{nd}, 2017

Beijing, China
Dear Colleagues and Friends,

On behalf of the organizing committee, it is my great pleasure to announce that the International Symposium in Quantitative Pharmacology (ISQP) will be held on December, 2017, Beijing, China.

The integration of PK and PD modeling and simulation have played a vital role to guide the decision making process on optimization and product realization, virtually in every stage to reduce time and cost needed for drug development.

With the recent trend toward global drug development and clinical trials, China has been regarded as the next frontier for the pharmaceutical industry. Pfizer, Roche, Johnson & Johnson, GSK, Novartis and others have established Research and Development (R&D) centers in China. Also, through the government support, the pharmaceutical industry and related infrastructure have been growing rapidly in China.

The success of previous three ISQPs since 2007 in China has created a big momentum in promoting the related research in this field in China. We believe that ISQP Beijing 2017 will also lend a platform for the scientific leaders in academia, regulatory authority and the pharmaceutical industry. It will be an opportunity to discuss the opportunities and challenges ahead in global drug research and development. We hope this symposium will contribute to enhance exchanging mutual interests between Western and China in this very challenging area.

As the capital of China with a history for more than 3000 years, Beijing, a rapidly changing city will present you a cultural experience with a mixture of old tradition and hi-technology during the stay.

Thank you in advance for your participation and support.

Pei Hu, PhD
President of the Organizing Committee
Professor, Director
Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Science
Committees

Chairman

Honorary Chairman: Professor Ruiyuan Sun, Honorary Chairman of the Quantitative Pharmacology Professional Committee of Chinese Pharmacological Society

Meeting Chairman: Professor Qingshan Zheng, Shanghai University of Traditional Chinese Medicine

Executive Chairman: Professor Pei Hu, Peking Union Medical College Hospital and Chinese Academy of Medical Science

Meeting Vice Chairman:

Prof. Lu Wei, School of pharmacy, Peking University

Prof. Jiang Ji, Peking Union Medical College Hospital

Dr. Huang Qin, CFDA drug review center,

Prof. Cheng Neneng, School of pharmacy, Fudan University

Prof. Jiao Zheng, Huashan Hospital affiliated to Fudan University

International Academic Committee (in alphabetical order by last name):

Andrew Chow
Nick Holford
Yanjin Jin
Jianguo Li
Bob Powell
Amin Rostami-Hodjegan
Tom Sun
Liang Zhao

Amgen
Univ. of Auckland
Genetech
AstraZeneca
Univ.of North Carolina State
Univ. of Manchester
Janssen
FDA

Joga Gobburu
William J. Jusko
Brian Corrigan
Donald E. Mager
Richard Peck
Amar Sharma
Yaning Wang
Ping Zhao

Univ. of Maryland
SUNY at Buffalo
Pfizer
SUNY at Buffalo
Roche
Janssen
FDA
The Bill & Melinda Gates Foundation

Chinese Academic Committee (in alphabetical order by last name):

Cheng Ze-neng, School of Pharmacy, ZhongNan University

Cui Yimin, No.1 Hospital of Peking University

Gao Chenyan, CFDA Center for drug evaluation

Guo Feng, Merck (Beijing) medicine research & Development Co Ltd
Huang Min, School of Pharmacy, Zhongshan University  
Huang Xiaohui, Medical University Of Anhui, School of pharmacy  
Jiang Ji, Peking Union Medical College Hospital  
Li Gailing, Johnson & Johnson  
Liu Xiaodong, Chinese Pharmacology University  
Liu Xiaoxi, Sanofi Aventis  
Li Haiyan, The 3rd Hospital of Peking University  
Li Yan, Institute of Medicine in Chinese Academy of Medical Sciences  
Ma Peimin, GSK  
Shi Jun, Roche pRED China  
Rui Jianzhong, General Hospital of Nanjing Military Area  
Song Haifeng, Military Medical Science Academy of the PLA  
Sun He, Tianshili company group  
Wang Guangji, Chinese Pharmacology University  
Wang Hainan, Division of Registration CFDA  
Wang Hui, Scholl of Traditional Chinese medicine, Guangdong Pharmaceutical University  
Wang Peng, Beijing Xiantongda Biological Medicine Technology Co Ltd  
Wang Xiaoliang, Institute of Medicine in Chinese Academy of Medical Sciences  
Xie Rujia, Pfizer (China) Co., Ltd.  
Xie Haitang, Anhui clinical evaluation center of drugs  
Yang Jinbo, CFDA centre for drug evaluation  
Yang Jin, Chinese Pharmacology University  
Yu Zhigang, Amgen  
Yang Guoping, Xiangya Third Hospital of Central South University  
Yuan Bingxiang, Xi'an Jiao Tong University School of Medicine  
Zhang Jing, Huashan Hospital affiliated to Fudan University  
Zhou Tianyan, School of pharmacy, Peking University  

Meeting Organization Committee  
Bi Shanshan, Johnson (China) Company  
Chen Rui, Peking Union Medical College Hospital  
Chen Xia, Peking Union Medical College Hospital  
Chen Yuancheng, Huashan Hospital affiliated to Fudan University  
Ding Junjie, Fudan University pediatric hospital  
Feng Sheng, Roche pRED China
Li Lujin, Shanghai University of Traditional Chinese Medicine
Liu Dongyang, Peking Union Medical College Hospital
Ma Guangli, Pfizer (China) Co., Ltd.
Nie Jing, Johnson (China) Company
Shang Dewei, Guangzhou Brain Hospital
Pei Qi, Xiangya Third Hospital of Central South University
Wang Hongyun, Peking Union Medical College Hospital
Wang Kun, Shanghai University of Traditional Chinese Medicine
Xiang Xiaoqiang, School of pharmacy; Fudan University
Yang Jiansong, Mousi company
Zhang Zhao, Institute of Medicine in Chinese Academy of Medical Sciences
Zhao Libo, Beijing Children’s Hospital
Zhao Wei, Shandong University
Zhao Qian, Peking Union Medical College Hospital
Zheng Xin, Peking Union Medical College Hospital

General Information
The time of the meeting: December 1\textsuperscript{st}-2\textsuperscript{nd}, 2017
The meeting place: Landmark Towers Hotel, Beijing, China
Location: North Dongsanhuan Road (Dongsanhuan Bei Lu), Yansha Commercial Area, Beijing, 100004, China

Important Date :
Oct. 10\textsuperscript{th}, 2017—Closing Date for the Early-bird Registration
Oct. 10\textsuperscript{th}, 2017—Closing Date for the Essay Contribute
Nov. 30\textsuperscript{th}, 2017—On-site registration Date
Dec. 1\textsuperscript{st}-2\textsuperscript{nd}, 2017 —The Formal Agenda of Convention and Exhibition

Registration Website: http://isqp2017.medmeeting.org/4452?lang=cn

Registration Fee:
$600 for one adult, $550 for one adult Early-bird Registration (Oct. 10\textsuperscript{th} included)
$300 for one Student (Student ID is NEEDED While Registration)
Organizing Committee will offer working lunch and welcome dinner.
Accommodation will be carried out under the unified arrangement by organizing committee, and the cost at audience’s own expense

Contact:
Hotline: +86-10-69106576, +86-10-69108356
Contact Person: Hongyun Wang, Ph D; Dongyang Liu, Ph D
Email: isqp2017@163.com
Fax: +86-10-69106576
Address: No 41, Damucang Hutong, Xicheng District, Beijing
Conference Agenda
(to be updated)

Dec. 1\textsuperscript{st}, 2017

Morning 7:30-12:10

7:30-8:30 Registration

8:30-8:50 Opening Ceremony

Chairs: Prof. Pei Hu and Prof. Qingshan Zheng\#

\# Session 1: Development of System Pharmacology

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:50-09:20</td>
<td>Mechanistic Basis of Systems Pharmacology</td>
<td>William J. Jusko, Prof. of SUNY at Buffalo, NY, USA</td>
</tr>
<tr>
<td>09:20-09:50</td>
<td>Breaking the Glass Ceiling: Examining the Perceived Hurdles to Quantitative Systems Pharmacology Modelling</td>
<td>Amin Rostami-Hodjegan, Prof. of University of Manchester, UK</td>
</tr>
</tbody>
</table>

#

Tea Break : 09:50-10:20

#

Session 2: The Impact of Quantitative Pharmacology on Decision and Strategy of Clinical Studies

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20-10:50</td>
<td>Current status of pharmacometrics on drug clinical development in China: cases and milestones</td>
<td>Qingshan Zheng, Shanghai University of Traditional Chinese Medicine</td>
</tr>
<tr>
<td>10:50-11:20</td>
<td>The role of clinical pharmacology in precision medicine</td>
<td>Richard Peck, MD/PhD, Global Head of pRED, Roche</td>
</tr>
<tr>
<td>11:20-11:50</td>
<td>Challenges and Opportunities in the Development of Neurodegenerative Treatments: The Role of Clinical Pharmacology and Pharmacometrics.</td>
<td>Brian Corrigan, PhD, Pfizer</td>
</tr>
</tbody>
</table>

Panel Discussion : 11:50-12:10 ( All the speakers )
Dec. 1st, 2017

Afternoon 13:30-17:30

Session 3: The Application and Future of Mechanism-based Physiological Pharmacokinetic Models and Disease Progression Model

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td>Disease progression modeling to inform the clinical development</td>
<td>Amar Sharma, Head of Global Clin. Pharm. and PM., Janssen</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Cancer Modeling Platform</td>
<td>Jin Yan Jin, Global Head of M&amp;S, Genetech</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>To be Determined</td>
<td>Jeff Barrett, Vice President, Translational Informatics, Sanofi</td>
</tr>
</tbody>
</table>

Tea Break: 15:00-15:30

Session 4: Model-based Drug Development Strategy in Biopharmaceutics

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-16:00</td>
<td>Translational Modeling of Target-Mediated Drug Disposition and Dynamics</td>
<td>Donald E. Mager, Prof. of SUNY at Buffalo, NY, USA</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Application of PBPK models in development of therapeutic antibodies</td>
<td>Yanguang Cao, Assistant Prof. of UNC at Chapel Hill, NC, USA</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>PKPD modeling to guide biologics clinical development plan</td>
<td>Tom Sun, Senior Director, Janssen.</td>
</tr>
</tbody>
</table>

Panel Discussion: 17:00-17:30 (All the speakers)
**Session 5: The Current Status and Future of Quantitative Pharmacology in Drug Evaluation from the Perspective of Regulation Authority**

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Balance between empiricism and mechanism</td>
<td>Yaning Wang, Director, Division of PM, CDER/FDA, USA</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>To be Determined</td>
<td>Jinbo Yang, Division of Statistics and Clinical Pharmacology CDE/CFDA, China</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>PBPK: from academic research to routine use in drug development</td>
<td>Ping Zhao, The Bill &amp; Melinda Gates Foundation</td>
</tr>
</tbody>
</table>

Tea Break : 10:00-10:30

#

**Session 6: The Application of Quantitative Pharmacology in Personalized Medicine and Bioequivalence Evaluation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td>Precision Drug Dosing: The Ultimate Patient Centered Pharmacometrics Application to Improve Health</td>
<td>Bob Powell</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Determination of antibiotic treatment duration and drug resistance control: a new model-based approach</td>
<td>Jun Shi, PhD, Roche Innovation Center</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>To be Determined</td>
<td>Liang Zhao, Director of Division of Quantitative Methods &amp; Modeling, CDER/FDA, USA</td>
</tr>
</tbody>
</table>

Panel Discussion : 12:00-12:20 ( All the speakers )
Dec. 2\textsuperscript{nd}, 2017

Afternoon 13:30-17:30

Session 7: Invited Lectures by Young Researchers

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:50</td>
<td>To be Determined</td>
<td>Peking Union Medical College Hospital</td>
</tr>
<tr>
<td>13:50-14:10</td>
<td>Novel pharmacotherapeutic quantitative guideline: our practice</td>
<td>Lujin Li, PhD, Shanghai University of Traditional Chinese Medicine</td>
</tr>
<tr>
<td>14:10-14:30</td>
<td>In vitro-in vivo extrapolation and preclinical-to-clinical scaling of glucocorticoids in the treatment of pancreatic cancer</td>
<td>Qingyu Yao, Peking University</td>
</tr>
<tr>
<td>14:30-14:50</td>
<td>Application and perspective of population pharmacokinetics in drug review</td>
<td>Hongchan Han, Division of Statistics and Clinical Pharmacology, CDE/CFDA, China</td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>Mechanism-based modeling and simulation of the time-kill curve: the biological resistance vs chemical reaction kinetics</td>
<td>Xiaofen Liu, Fudan University Huanshan Hospital</td>
</tr>
</tbody>
</table>

#

Tea Break: 15:10-15:40

Session 8: Invited Lectures by Young Researchers

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40-16:00</td>
<td>To be Determined</td>
<td>Peking Union Medical College Hospital</td>
</tr>
<tr>
<td>16:00-16:20</td>
<td>To be Determined</td>
<td>Qi Pei, Xiangya Third Hospital</td>
</tr>
<tr>
<td>16:20-16:40</td>
<td>Cloud computing in the modeling and simulation</td>
<td>Lixuan Qian, Fudan University Huanshan Hospital</td>
</tr>
<tr>
<td>16:40-17:00</td>
<td>Impact beyond Gut: a PBPK model for liposome property-performance translation</td>
<td>Hua He, China Pharmaceutical University#</td>
</tr>
<tr>
<td>17:00-17:20</td>
<td>PK prediction in patients with impaired renal function using PBPK, a case study</td>
<td>Sheng Feng, Roche China#</td>
</tr>
</tbody>
</table>

Closing ceremony: 17:20-17:30